TQB2102
Phase 3Small molecule
TQB2102 is one of 94 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
3
Indications
5
Total Trials
5
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer3 trials
Colorectal Cancer1 trial
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Not yet recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07483684·142 enrolled
Advanced Cancers1 trial
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Active, not recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT05735496·219 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQB2102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details